

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Tezacaftor with ivacaftor combination therapy for treating cystic fibrosis with the F508del mutation [ID1303]

Matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company</u></p> <ul style="list-style-type: none"> Vertex Pharmaceuticals (tezacaftor, ivacaftor) <p><u>Patient/carer group</u></p> <ul style="list-style-type: none"> British Lung Foundation Contact a Family Cystic Fibrosis Care Cystic Fibrosis Trust Genetic Alliance Genetic Disorders UK Jnetics Muslim Council of Britain South Asian Health Foundation Specialised Healthcare Alliance Together for Short Lives <p><u>Professional groups</u></p> <ul style="list-style-type: none"> Association of Genetic Nurses and Counsellors Association of Respiratory Nurse Specialists British Society for Genetic Medicine British Thoracic Society Chartered Society of Physiotherapy Cystic Fibrosis Nurses Association Primary Care Respiratory Society UK Royal College of General Practitioners Royal College of Nursing Royal College of Pathologists Royal College of Physicians Royal Pharmaceutical Society Royal Society of Medicine UK Clinical Pharmacy Association UK Genetic Testing Network 	<p><u>General</u></p> <ul style="list-style-type: none"> All Wales Therapeutics and Toxicology Centre Allied Health Professionals Federation Board of Community Health Councils in Wales British National Formulary Care Quality Commission Department of Health, Social Services and Public Safety for Northern Ireland Healthcare Improvement Scotland Medicines and Healthcare Products Regulatory Agency National Association of Primary Care National Pharmacy Association NHS Alliance NHS Confederation Scottish Medicines Consortium Welsh Health Specialised Services Committee <p><u>Comparator companies</u></p> <ul style="list-style-type: none"> AbbVie (pancreatin) Allergan UK (carbocisteine, nebulised hypertonic sodium chloride) Essential Pharmaceuticals (pancreatin) Janssen (pancreatin) Merck Serono (pancreatin) Pari Medical (nebulised hypertonic sodium chloride) Pharmaxis (mannitol dry powder for inhalation) Roche Products (dornase alfa) Sanofi (carbocisteine) Teva (carbocisteine)

Matrix for the single technology appraisal of tezacaftor with ivacaftor combination therapy for treating cystic fibrosis with the F508del mutation. Issue date: May 2018.

Consultees	Commentators (no right to submit or appeal)
<p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health • NHS England • NHS Central London CCG • NHS West Leicestershire CCG • Welsh Government 	<ul style="list-style-type: none"> • Zentiva (carbocisteine) <p><u>Relevant Research Groups</u></p> <ul style="list-style-type: none"> • British Association for Lung Research • CF Unite • Cochrane Airways Group • Cochrane Cystic Fibrosis and Genetic Disorders Group • MRC Clinical Trials Unit • National Institute for Health Research • UK Cystic Fibrosis Gene Therapy Consortium <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Appraisal Determination (FAD).

All non company consultees are invited to submit a statement¹, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary).

All non company commentators are invited to nominate clinical or patient experts.

¹ Non company consultees are invited to submit statements relevant to the group they are representing.